Sankyo halts CS-917 diabetes program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sankyo and partner Metabasis are halting development of their type 2 diabetes agent CS-917 following two cases of apparent lactic acidosis in a Phase II interaction study with metformin, Metabasis says March 16. Two trials have been halted and "a third study evaluating various doses of CS-917 administered as a single agent over three months is under review," the firm says. Metabasis maintains that the efficacy data for the gluconeogenesis/fructose bisphosphatase inhibitor are "promising"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.